Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter.

Endogenous isoquinoline (IQ) derivatives structurally related to the selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite 1-methyl-4-phenylpyridine (MPP(+)) may contribute to dopaminergic neurodegeneration in Parkinson's disease. We addressed the importance of the DAT molecule for selective dopaminergic toxicity by testing the differential cytotoxicity of 22 neutral and quaternary compounds from three classes of isoquinoline derivatives (3, IQs; 4,3,4-dihydroisoquinolines and 15, 1,2,3,4-tetrahydroisoquinolines) as well as MPP(+) in non-neuronal and neuronal heterologous expression systems of the DAT gene (human embryonic kidney HEK-293 and mouse neuroblastoma Neuro-2A cells, respectively). Cell death was estimated using the MTT assay and the Trypan blue exclusion method. Nine isoquinolines and MPP(+) showed general cytotoxicity in both parental cell lines after 72hr with half-maximal toxic concentrations (TC(50) values) in the micromolar range. The rank order of toxic potency was: papaverine>salsolinol=tetrahydropapaveroline=1-benzyl-TIQ=norsalsolinol>tetrahydropapaverine>2[N]-methyl-salsolinol>2[N]-methyl-norsalsolinol>2[N]-Me-IQ(+)=MPP(+). Besides MPP(+), only the 2[N]-methylated compounds 2[N]-methyl-IQ(+), 2[N]-methyl-norsalsolinol and 2[N]-methyl-salsolinol showed enhanced cytotoxicity in both DAT expressing cell lines with 2- to 14-fold reduction of TC(50) values compared to parental cell lines. The rank order of selectivity in both cell systems was: MPP(+)>>2[N]-Me-IQ(+)>2[N]-methyl-norsalsolinol=2[N]-methyl-salsolinol. Our results suggest that 2[N]-methylated isoquinoline derivatives structurally related to MPTP/MPP(+) are selectively toxic to dopaminergic cells via uptake by the DAT, and therefore may play a role in the pathogenesis of Parkinson's disease.

[1]  S. Ohta,et al.  Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate , 1996, Neuroscience Letters.

[2]  Alexis Elbaz,et al.  Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study , 1999, The Lancet.

[3]  M. Naoi,et al.  Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies , 1996, Brain Research.

[4]  M. Naoi,et al.  Effects of various tetrahydroisoquinoline derivatives on mitochondrial respiration and the electron transfer complexes , 1998, Journal of Neural Transmission.

[5]  A. Ludolph,et al.  Protective Effects of Riluzole on Dopamine Neurons , 2000, Journal of neurochemistry.

[6]  S. Ohta,et al.  1‐Benzyl‐1,2,3,4‐Tetrahydroisoquinoline as a Parkinsonism‐Inducing Agent: A Novel Endogenous Amine in Mouse Brain and Parkinsonian CSF , 1995, Journal of neurochemistry.

[7]  P. Vieregge,et al.  Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease , 1995, Journal of the Neurological Sciences.

[8]  F. Hefti,et al.  Toxicity of 1‐Methyl‐4‐Phenylpyridinium for Rat Dopaminergic Neurons in Culture: Selectivity and Irreversibility , 1990, Journal of neurochemistry.

[9]  M. Naoi,et al.  A neurotoxin N-methyl(R)salsolinol induces apoptotic cell death in differentiated human dopaminergic neuroblastoma SH-SY5Y cells , 1997, Neuroscience Letters.

[10]  S. Ohta,et al.  Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter. , 1998, European journal of pharmacology.

[11]  G. Uhl,et al.  Parkinsonism‐inducing neurotoxin MPP+: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA , 1992, Annals of neurology.

[12]  C. Marsden,et al.  Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Biochemical pharmacology.

[13]  A. Brossi,et al.  Alkaloids in mammalian tissues. 2. Synthesis of (+)-and (-)-1-substituted-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. , 1972, Journal of medicinal chemistry.

[14]  S. Ohta.  Isoquinolines in Parkinson’s Disease , 2000 .

[15]  H. Griffiths,et al.  Studies on the neurotoxicity of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in SH-SY5Y cells. , 1995, European journal of pharmacology.

[16]  M. Caron,et al.  Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. , 1996, The Journal of pharmacology and experimental therapeutics.

[17]  M. Naoi,et al.  An Endogenous Dopaminergic Neurotoxin, N‐Methyl‐(R)‐Salsolinol, Induces DNA Damage in Human Dopaminergic Neuroblastoma SH‐SY5Y Cells , 1997, Journal of neurochemistry.

[18]  C. Marsden,et al.  Toxicity to PC12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 1996, Neuroscience Letters.

[19]  M. Naoi,et al.  N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. , 1993, Advances in neurology.

[20]  A. Ludolph,et al.  HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism , 1999, Neurochemistry International.

[21]  A. Brossi,et al.  Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines. , 1990, Journal of medicinal chemistry.

[22]  A. Marini,et al.  The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  S. P. Hunt,et al.  Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea , 1988, Neuroscience.

[24]  M. Naoi,et al.  (R) salsolinol N‐methyltransferase activity increases in parkinsonian lymphocytes , 1998, Annals of neurology.

[25]  S. Amara,et al.  Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Storch,et al.  6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism , 2000, Journal of Neural Transmission.

[27]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[28]  G. Uhl.  Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease , 1998, Annals of neurology.

[29]  C. Marsden,et al.  Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1996, Biochemical pharmacology.

[30]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[31]  T. Nagatsu,et al.  An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.

[32]  H J Gundersen,et al.  The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[33]  R. Gainetdinov,et al.  Dopamine Transporter Is Required for In Vivo MPTP Neurotoxicity: Evidence from Mice Lacking the Transporter , 1997, Journal of neurochemistry.

[34]  Y. Mizuno,et al.  Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain , 1992, Journal of the Neurological Sciences.

[35]  K. Kikuchi,et al.  Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-Tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[36]  D. L. Le Couteur,et al.  Association of a polymorphism in the dopamine‐transporter gene with parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[37]  Y. Mizuno,et al.  Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture , 1997, Brain Research.

[38]  C D Marsden,et al.  Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. , 1998, Biochemical pharmacology.

[39]  M. Tohyama,et al.  Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells , 1998, Neuroscience Research.

[40]  G. Cohen,et al.  Tetrahydroisoquinoline alkaloids: uptake by rat brain homogenates and inhibition of catecholamine uptake. , 1971, The Journal of pharmacology and experimental therapeutics.

[41]  A. Zaritsky,et al.  Effect of nebulized ipratropium on the hospitalization rates of children with asthma. , 1998, The New England journal of medicine.

[42]  G. Stern,et al.  Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man , 1973, Nature.

[43]  C. Marsden,et al.  Inhibition of alpha-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1995, Neuroreport.

[44]  T. Kawarai,et al.  A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease , 2000, Annals of neurology.

[45]  A. Storch,et al.  Neurotoxic Factors in Parkinson’s Disease and Related Disorders , 2000, Springer US.

[46]  H. Tohgi,et al.  A dopaminergic neurotoxin, (R)‐N‐methylsalsolinol, increases in parkinsonian cerebrospinal fluid , 1996, Annals of neurology.

[47]  Johannes Schwarz,et al.  1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism , 2000, Brain Research.

[48]  M. Naoi,et al.  Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. , 1990, Journal of chromatography.

[49]  D. Kömpf,et al.  Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. , 1992, Life sciences.

[50]  M. Naoi,et al.  Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. , 1993, Advances in neurology.

[51]  C. Marsden,et al.  Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. , 1996, Biochemical pharmacology.

[52]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Anders Björklund,et al.  Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.

[54]  M. Caron,et al.  Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  G. Uhl,et al.  Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. , 1993, Brain research. Molecular brain research.

[56]  S. Hersch,et al.  Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra , 1997, The Journal of comparative neurology.